[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: 50 patients with COVID-19 who receive routine antiviral treatment and chloroquine, have more than normal levels of TNF-\u03b1, and are at risk of critical disease statement (1-respiratory failure that needs mechanical ventilation, 2-shock, 3-any organ failure, 4-need to be admitted in ICU) will receive subcutaneous injection of anti-TNF-\u03b1 (adalimumab), 40 mg, in periumbilical region of the abdomen. According to altered clinical and laboratory findings, mentioned dose can be repeated", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsControl group: 50 matched patients receiving equal antiviral treatment and chloroquine", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 27, "treatment_name": "Adalimumab", "treatment_type": "Other targeted therapies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]